Thomas Jefferson University

Main menu:

Gastrointestinal Oncology Program

The Gastrointestinal Oncology Program is led by Edith Mitchell, MD, FACP, who was the recipient of the Cancer Care award for Physician of the Year (2010) and is co-principal investigator on a recently awarded Komen Promise grant. Her clinical focus has been on colorectal cancer and the exploration of new systemic therapies. Her work with epidermal growth factor receptor inhibitors and management of the associated scan toxicity has been set as the international standard of care. She is also a pivotal component of our diversity program within the Kimmel Cancer Center. Dr. Mitchell collaborates closely with Dr. Susan Littman whose primary focus is on developing novel therapies for pancreatic cancer and has been responsible for developing the cancer genetics program within the department. Nancy Lewis, MD is the leader of the Liver Tumor section and has a special clinical interest in new drug developments.MadhavanPillai, MD was hired to assist Dr. Klein in the inpatients service but also spends one day a week seeing outpatient in the Gastro-intestinal clinic with an interest in neuroendocrine tumors of the GI tract.

Program Physicians:
Nancy Lewis, MD
Susan J. Littman, MD
Edith P. Mitchell, MD, FACP
Madhaven Pillai, MD

For further information contact:
Thomas Jefferson University Hospital

Gastrointestinal Cancer Facts

Gastrointestinal cancer is malignancy of the digestive system – including the esophagus, stomach, gallbladder and bile duct, biliary liver, pancreas, small intestine, large intestine (colon), rectum and anus.

The number of new gastrointestinal cancer cases occurring in the United States annually totals more than 250,000. Colorectal cancer is the third most common cancer in men and women, with an estimated 105,000 colon cancer and 40,000 rectal cancer diagnoses in the United States each year. Pancreatic and stomach cancer diagnoses each year total 32,000 and 22,000 cases respectively.

Benign tumors are not cancerous. In the GI tract benign tumors, called polyps, may form. Because of the potential for these benign tumors to become cancerous, polyps should be removed.